Related Experiment Video
Updated: Jun 12, 2026

Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology
Published on: May 23, 2025
Prevalence of Helicobacter pylori positivity in patients undergoing percutaneous coronary intervention
C Hiew1, A Duggan, T de Malmanche
1Cardiovascular Unit, John Hunter Hospital, University of Newcastle, Newcastle, New South Wales, Australia.
Insights
Helicobacter pylori infection is present in 37% of patients undergoing percutaneous coronary intervention (PCI). This infection may increase the risk of gastrointestinal bleeding in patients receiving antiplatelet therapy after PCI.
Area of Science:
- Cardiology
- Gastroenterology
- Infectious Disease
Background:
- Haemorrhagic complications after percutaneous coronary intervention (PCI) significantly impact patient outcomes.
- Helicobacter pylori (H. pylori) infection is a known cause of peptic ulcer disease, particularly in patients using non-steroidal anti-inflammatory drugs.
- The prevalence of H. pylori in patients undergoing PCI and receiving antiplatelet therapy is not well-documented.
Purpose of the Study:
- To determine the prevalence of H. pylori positivity in patients undergoing PCI.
- To identify features associated with H. pylori positivity in this patient group.
Main Methods:
- A cohort of 245 patients undergoing PCI between August 2008 and April 2009 were identified.
- H. pylori positivity was assessed using a commercially available enzyme-linked immunosorbent assay (ELISA) for serological status.
Main Results:
- 37% of patients (91 out of 245) tested positive for H. pylori serology.
- A significant proportion (75%) of H. pylori positive patients were on medications known to increase gastrointestinal bleeding risk.
- H. pylori positive patients were generally older and had higher creatinine levels, often receiving proton pump inhibitor therapy.
Conclusions:
- H. pylori positivity was detected in 37% of an unselected PCI cohort, representing a potential, treatable cause of bleeding.
- This prevalence suggests H. pylori is a significant factor for patients on dual antiplatelet therapy post-PCI.
- Further research is needed to establish the link between H. pylori positivity and adverse gastrointestinal and cardiac outcomes.
Background:
The adverse effect of haemorrhagic complications after percutaneous coronary intervention (PCI) on outcome is well established with Helicobacter pylori infection known to be an important precipitant of peptic ulcer disease in patients receiving non-steroidal anti-inflammatory drug therapy. The prevalence of H. pylori positivity in patients undergoing PCI and receiving subsequent antiplatelet therapy is unknown.
Aims:
We sought to determine the prevalence and features associated with H. pylori positivity in patients undergoing PCI.
Methods:
All patients undergoing PCI between August 2008 and April 2009 were identified and assessed for H. pylori positivity with serological status determined by using a commercially supplied enzyme-linked immunosorbent assay.
Results:
A total of 245 patients undergoing PCI during the study period had samples obtained for H. pylori serology. Of these, 91 were positive for H. pylori serology (37%) and 148 were negative (60%) with six samples being equivocal (3%). Of those patients positive for H. pylori, 75% were on agents at admission known to promote or precipitate gastrointestinal haemorrhage. Patients positive for H. pylori tended to be older, with increased creatinine and more likely to be receiving proton pump inhibitor therapy.
Conclusions:
In an unselected cohort of patients undergoing PCI in a single centre, we detected a prevalence of H. pylori positivity in 37% of patients; this denotes a potentially treatable precipitant of haemorrhage in a considerable portion of patients receiving dual antiplatelet therapy after PCI. Further prospective study is required to determine if the presence of H. pylori positivity is associated with adverse events in terms of gastrointestinal and cardiac outcomes.
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer
Gastritis II: Pathophysiology
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease I: Introduction
